IRadimed Corporation

NASDAQ:IRMD

Medical - Devices

Healthcare
$82.31 +0.73%

+$0.67 today

Market cap
$1.05B
Beta
0.92
P/E (TTM)
49.7
EPS (TTM)
$1.85
Dividend yield
1.35%
52W Low $55.11High $107.90

Volume 0.08M

Average 0.12M

IRMD EBITDA Margin

EBITDA as a percentage of revenue.

IRadimed CorporationNASDAQ: IRMD

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 37.4%

EBITDA Margin was 37.4% in Q1 FY2026, up 5.9 pp from a year earlier. On a trailing-twelve-month basis it was 37.4%, up 3.1 pp year over year. Over 3 fiscal years it widened by 5.1 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 38.2% for the fiscal year ending Dec 2026, up from 36.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
37.4%+0.4 pp QoQ
Last fiscal yearDec 2025
36.7%+2.4 pp YoY
LTMMar 2026
37.4%+3.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+5.9 pp-3.0 pp-8.9 pp
1 year+2.4 pp+1.5 pp-0.9 pp
3 years+5.1 pp+5.3 pp+0.3 pp
5 years+4.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
36.7%
Year-over-year change
+2.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How IRMD compares with its peers on the latest reported figures

  • IRMD's LTM Mar 2026 EBITDA Margin of 37.4% is the 2nd highest of the 11 companies compared; the peer median is 4.4%.
  • Its year-over-year change of +3.1 pp is the 4th highest of 11, against a peer median of -5.3 pp.
  • Over three fiscal years its change of +5.1 pp compares with a peer median of +15.8 pp.
IRMD Competitors Peer median
EBITDA Margin for IRMD and competitors
Company Period LTM level YoY 3-year change
CTEVClaritev CorporationLTM Mar 202652.9% +109.3 pp+34.6 pp
IRMDIRadimed CorporationLTM Mar 202637.4% +3.1 pp+5.1 pp
INMDInMode Ltd.LTM Mar 202627.5% -8.4 pp-14.5 pp
GDRXGoodRx Holdings, Inc.LTM Mar 202622.0% +0.5 pp+14.6 pp
AHCOAdaptHealth Corp.LTM Apr 202616.2% -7.4 pp-5.7 pp
MDXGMiMedx Group, Inc.LTM Mar 202614.7% -3.3 pp+23.8 pp
CRONCronos Group Inc.LTM Mar 2026-5.9% +25.2 pp+103.0 pp
OPKOPKO Health, Inc.LTM Mar 2026-6.0% -27.8 pp+20.2 pp
TNDMTandem Diabetes Care, Inc.LTM Mar 2026-7.0% +6.7 pp-8.0 pp
AXGNAxoGen, Inc.LTM Sep 2026-8.0% -18.0 pp+17.0 pp
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026-17.6% -28.7 pp-44.6 pp
Peer median (excluding IRMD) 4.4%-5.3 pp+15.8 pp

Competitors are the stored peer set for IRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue41.81M53.3M65.56M73.24M83.81M
Cost of Revenue9.76M12.02M15.4M16.89M19.49M
Gross Profit32.05M41.28M50.16M56.35M64.32M
Gross Margin76.6%77.4%76.5%76.9%76.7%
Research & Development1.91M2.28M2.86M2.83M2.98M
Selling, General & Admin20.33M23.38M27.26M31.55M35.2M
Operating Expenses22.23M25.65M30.12M34.39M38.18M
Depreciation & Amortization1.41M670.67K765.18K817.66K2.38M
EBITDA11.24M16.85M22.5M25.09M30.74M
EBITDA Margin26.9%31.6%34.3%34.3%36.7%
Operating Income9.82M15.63M20.04M21.96M26.15M
Operating Margin23.5%29.3%30.6%30.0%31.2%
Interest Income34.81K581.85K1.86M2.19M0
Interest Expense00000
Other Income / Expenses18.61K553.1K1.7M2.31M2.21M
Income Before Tax9.84M16.18M21.74M24.28M28.36M
Pre-Tax Margin23.5%30.4%33.2%33.1%33.8%
Income Tax Expense510.82K3.35M4.55M5.04M5.88M
Net Income9.33M12.83M17.19M19.23M22.48M
Net Margin22.3%24.1%26.2%26.3%26.8%
EPS (Basic)0.761.021.361.521.77
EPS (Diluted)0.741.021.351.501.75
Weighted Avg Shares12.35M12.56M12.6M12.67M12.72M
Weighted Avg Shares (Diluted)12.59M12.64M12.72M12.78M12.85M

IRadimed Corporation

NASDAQ:IRMD

Intrinsic Alpha fair value

Locked

Current Price

$82.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.